This Article Full Text (PDF) All Versions of this Article: 1352458507084107v1 1352458507084107v2 14/3/425    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mehta, L. R Articles by Schwid, S. R Search for Related Content PubMed PubMed Citation Articles by Mehta, L. R Articles by Schwid, S. R Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome

Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA, lahar_mehta{at}urmc.rochester.edu

Melissa K Samuelsson

Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

Anatole K Kleiner

Allergy, Immunology and Rheumatology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

Andrew D Goodman

Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

Jennifer H Anolik

Allergy, Immunology and Rheumatology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

R John Looney

Allergy, Immunology and Rheumatology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

Steven R Schwid

Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system characterized by severe episodes of optic nerve and spinal cord inflammation. NMO-IgG (anti-aquaporin-4) has been recently described as a sensitive and specific marker for NMO. As there have been prior published reports of an association between NMO and systemic autoimmune diseases, the prognostic value of the antibody test in these cases is uncertain. We describe a 47-year old woman with recurrent transverse myelitis and a long-standing history of systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APLS). While she did not have a history of optic neuritis, serological testing for the NMO-IgG was positive when she was admitted for her second episode of transverse myelitis. Testing for the NMO-IgG in cases of isolated or recurrent transverse myelitis attributed to current SLE and APLS may help clarify the diagnosis of a distinct disease process likely to cause recurrent and severe disability, warranting more aggressive immunotherapy. Multiple Sclerosis 2008; 14: 425—427. http://msj.sagepub.com

Key Words: anti-phospholpid antibody syndrome • neuromyelitis optica • NMO-IgG • systemic lupus erythematosus

This version was published on April 1, 2008

Multiple Sclerosis, Vol. 14, No. 3, 425-427 (2008)
DOI: 10.1177/1352458507084107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?